Program Details

The program below is subject to change. Please sign up for updates to be notified when information becomes available.  

 

EDUCATIONAL DAY - Wednesday 11 May 2022

Cardiac genetics for beginners:
Introductory program in inherited cardiovascular conditions for cardiologists, trainees and allied health staff
Time Talk Title  Speaker
1230 Arrival and registration   
1300 Introduction: Family history- the gene genie Jon Skinner (NZ)
Session 1: Genetics
Chair: Jonathan Skinner
Time Talk Title  
1310-1330 Cellular genetics, the basics: Talk like a geneticist  Paul James (VIC)
1330-1350 The essentials of genetic testing  Richard Bagnall (NSW)
1350-1405 Clinical conditions: The cardiomyopathies  Belinda Gray (NSW)
1405-1420 Clinical conditions: The cardiac ion channelopathies  Hariharan Raju (NSW)
1420-1435 Clinical conditions: Familial Hypercholesterolaemia and coronary artery syndromes  Gerald Watts (WA)
1435-1505 Familial Aortopathies  Dominica Zentner (VIC)
1505-1535 Afternoon Break  
Session 2: Preparation and counselling for a genetic test
Chair: Jonathan Skinner
Time Talk Title Speaker
1535-1550 Before the genetic test: Defining the clinical phenotype  Kathryn Waddell-Smith (SA)
1550-1605 Before the genetic test: Defining probabilities and managing expectations  Robyn Hylind (USA)
1605-1620 Dealing with the genetic result and the clinical fallout  Dominic Abrams (USA)
Session 3: Questions, discussion and illustrative cases with audience participation

Chairs: Dominic Abrams, Jodie Ingles and Megan Higgins
Time Talk Title Speaker
1620-1640 Case 1  Stacey Peters (NSW)
1640-1700 Case 2  Helen Mountain (WA)
1700-1720 Case 3  Ivan Macciocca (VIC)

 

wwwwwwwwWRerrX

PROGRAM - DAY 1 - Thursday 12 May 2022

Session 1: Opening Session

Chairs: John Atherton and Julie McGaughran
Time Talk Title  Speaker
0800-0810 Welcome John Atherton and Julie McGaughran,
Conference Co-Convenors
0810-0820 Official Opening  Her Excellency the Honourable Dr Jeannette Young PSM
Governor of Queensland
0820-0830 Program highlights Chris Semsarian (NSW)
0830-0915 Personalised medicine in inherited cardiomyopathies Perry Elliott (UK)
0915-1000 Therapies for RASopathy related hypertrophic cardiomyopathy Bruce Gelb (USA)
1000-1030 Morning Break  

Session 2: What’s new in the inherited cardiomyopathies?

 

Chairs: Nikki Bart (NSW) and Hariharan Raju (NSW)

  
Time Talk Title Speaker
1030-1050 Arrhythmogenic cardiomyopathy: sorting the wheat from the chaff Perry Elliott (UK)
1050-1105 What’s new in HCM?

 

 Vimal Patel (WA)
1105-1125 What’s new in DCM? Stacey Peters (VIC)
1125-1140 What’s new in ACM? Haris Haqqani (QLD)
1140-1155 Cohort studies in the inherited cardiomyopathies Jodie Ingles (NSW)
Session 3: Genetic Testing for Familial hypercholesterolaemia
 Chairs: Liz Robertson (NSW) and Gerald Watts (WA)
Time Talk Title Speaker 
1030-1045 Genetic testing and NHG Policy Framework Gerald Watts (WA)
1045-1100 The MSAC application and the MBS item David Sullivan (NSW)
1100-1115 The cardiology perspective Kathryn Wadell-Smith (SA)
1115-1130 What is the role of primary care? Jan Radford (TAS) 
1130-1145 Implementation science: Making it happen

Mitchell Sarkies (NSW)
               
1200-1330 Lunch  
1220-1320 Sponsored Lunch Symposium Hosted by Novartis Australia Pty Ltd
RNA therapeutics is a rapidly emerging field. The translation of RNA biology into robust therapeutics has been made possible by advances in design and delivery methods. Recognising this exciting evolution in the field of cardiovascular medicine, we invite you to attend this symposium which will cover the:

- Residual risk concept in cardiovascular disease
- Principles behind the design of RNA therapeutics
- Optimisation of nucleic acid based drugs for therapeutic application (intracellular delivery, stability and immune response activation)
- Application to genetically validated targets
- A review of the clinical evidence to date		 Chair - John Atherton 

RNA therapeutics for the management of dyslipidaemia’s
Gerald Watts (WA)

David Sullivan (NSW)
Session 4: Latest in the inherited arrhythmia syndromes
Chairs: Raymond Sy (NSW) and Kathryn Waddell-Smith (SA) 
Time Talk Title Speaker
1330-1350 Management pearls in CPVT Andreas Pflaumer (VIC)
1350-1405 Genotype-guided therapies in LQTS Belinda Gray (NSW)
1405-1420 What is Brugada syndrome in 2022? Jason Davis (QLD)
1420-1435 Insights from iPSC models Annika Winbo (NZ)
1435-1450 In vitro assessment of LQTS variants Andy Ng (NSW)
Session 5: Genetics in 2022
Chairs: Ari Horton (VIC) and Sonia Shah (QLD)
Time Talk Title Speaker
1330-1345 Polygenic risk scores in cardiovascular disease

Gad Abraham (VIC)
1345-1400 The role of genome sequencing

 

 Richard Bagnall (NSW)
1400-1415 Genomics and PRS in heart failure Sonia Shah (QLD)
1415-1430 Polygenic risk scores: where are we heading Paul Lacaze (VIC)
1430-1445 Human cardiac organoids: An enabling
technology for functional genomics		 Mark Pocock (QLD)
1445-1500 Key role of the cardiac nurse in a cardiac genetic service  Tina Thompson (VIC)
1500-1530 Afternoon Break  
Session 6: Clinical, genetic and functional aspects of congenital heart disease

 Chairs: 
Time Talk Title Speaker
1530-1550 The genetic architecture of congenital heart disease Bruce Gelb (USA)
1550-1605 Where next for broad-scale genetic testing in CHD? Gillian Blue (NSW)
1605-1620 CHD genomics and gene discovery  
1620-1635 Pre-test genetic counselling: Preparing for universal whole genome sequencing Ivan Macciocca (VIC)
1635-1650 Relevance of genetic investigations in childhood heart failure Robert Weintraub (VIC)
Conference Dinner
1900-2300 Conference Dinner, Level 12 Rooftop, Rydges South Bank Brisbane  

 

sdfsdfsdfsfdsfsX

PROGRAM - DAY 2 - Friday 13 May 2022
0645-0800

Sponsored Breakfast Symposium Hosted by Sanofi:

0645-0710 Breakfast Available

0710-0715 Welcome and Introduction

0715-0745 A clinical approach to the diagnosis of hypertrophic cardiomyopathy

0745-0800 Q+A

 

 

Chris Semsarian (NSW)

Perry Elliott (UK)
Session 7: The great debate and Oral Abstract Prize Final
Chairs: Julie McGaughran and Chris Semsarian
Time Talk Title Speaker
0830-0915 Debate: Polygenic risk scores ready for cardiology clinic

FOR:  Paul James (VIC)

AGAINST: Edwin Kirk (NSW)
0915-1000 Oral Abstract Prize Final   
0915-0930  Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis Paul Lacaze (VIC)
0930-0945  Evaluating the Clinical utility of Polygenic Risk Score for Heart Failure Xiaodong Mo (QLD)
0945-1000  Contribution and functional characterisation of splice-disrupting variants in inherited heart disease and sudden cardiac death Emma Singer (NSW)
1000-1030 Morning Break  
Session 8: Resuscitated sudden cardiac arrest in the young
Chairs: Julia Isbister (NSW) and Andreas Pflaumer (VIC) 
Time Talk Title Speaker
1030-1045 Causes of sudden cardiac arrest in the young Elizabeth Paratz (VIC)
1045-1100 Investigation of a resuscitated cardiac arrest Martin Stiles (NZ)
1100-1115 Progress in preventing malignant arrhythmias Saurabh Kumar (NSW)
1115-1130 Sudden cardiac arrest in athletes: What’s different? Andre La Gerche (VIC)
1130-1145 Psychological support

 

 Claire O’Donovan (NZ)
Session 9: Latest advances in the familial aortopathies
 Chairs: Felicity Collins (NSW) and Dominica Zentner (VIC)
Time Talk Title Speaker
1030-1045 What's new in the aortopathies Dominica Zentner (VIC)
1045-1100 Latest in the genetics of aortopathies Elizabeth Robertson (NSW)
1100-1115  Aortopathy findings at post-mortem Johan Duflou (NSW)
1115-1130 Aortopathies in pregnancy William Parsonage (QLD)
1130-1150 Surgical approaches to aortopathies Livia Williams (QLD)
1200-1330 Lunch  
1220-1320 RNA therapeutics for managing dyslipidemias Hosted by Novartis Australia Pty Ltd
RNA therapeutics is a rapidly emerging field. The translation of RNA biology into robust therapeutics has been made possible by advances in design and delivery methods. Recognising this exciting evolution in the field of cardiovascular medicine, we invite you to attend this symposium which will cover the:

- Residual risk concept in cardiovascular disease
- Principles behind the design of RNA therapeutics
- Optimisation of nucleic acid based drugs for therapeutic application (intracellular delivery, stability and immune response activation)
- Application to genetically validated targets
- A review of the clinical evidence to date		 Chair - John Atherton 

RNA therapeutics for the management of dyslipidaemia’s
Gerald Watts (WA)

David Sullivan (NSW)
Session 10: National Collaborations and Case Presentations

Chairs: Belinda Gray and Paul James 
Time Talk Title Speaker
1330-1350 The Australian Genomics Initiative Tiffany Boughtwood (VIC)
1350-1400 The Cardiovascular Genetics Flagship - progress to date

Julie McGaughran (QLD)
1400-1430 Case Presentation #1 (Arrhythmia/SCD)

Panel Members:

Hariharan Raju

Haris Haqqani

Felicity Collins

Laura Yeates

Jo Duflou

Tina Thompson
1430-1500 Case Presentation #2 (Cardiomyopathy) 

Jamie Cham

 

Panel Members:

Perry Elliott

John Atherton

Diane Fatkin

Ivan Macciocca

Belinda Gray

Kathryn Waddell-Smith
1500-1530 Afternoon Break  
Session 11: Final plenary

Chairs: Julie McGaughran                                   

Time Talk Title Speaker
1530-1605  Precision medicine approach to congenital heart disease Bruce Gelb (USA)
1605-1640 Hypertrophic cardiomyopathy: What’s next? Perry Elliott (UK)
1640-1650 Thank you Chris Semsarian (NSW)
1650-1700 Official close of the Conference  John Atherton and Julie McGaughran,
Conference Co-Convenors 

 

MCcCCCCX
X
X
X
X